Prostatype Genomics AB (SE:PROGEN)
:PROGEN
Want to see SE:PROGEN full AI Analyst Report?
Top Page
Prostatype Genomics AB
(PROGEN)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.42
▼(-43.60% Downside)
Action:Reiterated
Date:05/21/26
The score is primarily constrained by weak financial performance (persistent losses, negative margins, and continued cash burn) with only the low/zero debt position as a partial offset. Technicals add further pressure given the price is below all key moving averages and MACD is negative. Valuation metrics provided do not offer clear support (P/E not meaningful and no dividend yield data).
Positive Factors
Low leverage / balance sheet flexibility
Zero reported debt materially reduces financial distress risk and preserves strategic flexibility. For a small diagnostics company burning cash, minimal leverage lowers near-term default risk and makes equity or partnership financing easier without servicing fixed interest, aiding durability.
Negative Factors
Persistent operating losses / weak margins
Deep and recurring operating losses indicate the cost base outstrips current commercial revenue materially. Without sustained revenue scale or significant margin improvements, losses will continue to erode equity and require external funding, threatening long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet flexibility
Zero reported debt materially reduces financial distress risk and preserves strategic flexibility. For a small diagnostics company burning cash, minimal leverage lowers near-term default risk and makes equity or partnership financing easier without servicing fixed interest, aiding durability.
Read all positive factors
Prostatype Genomics AB (PROGEN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr24.27M
Dividend YieldN/A
Average Volume (3M)300.11K
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue Growth198.49%
EPS Growth84.60%
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-11.20
Shares Outstanding59,189,320
10 Day Avg. Volume460,844
30 Day Avg. Volume300,114
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr1.23M
Prostatype Genomics AB Business Overview & Revenue Model
Company Description
Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision med...
How the Company Makes Money
Prostatype Genomics generates revenue primarily by selling its prostate cancer prognostic testing offering (the Prostatype test) for use in clinical care and/or through laboratory and diagnostic-service channels. This typically involves per-test r...
Prostatype Genomics AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 716.00K | 594.00K | 199.00K | 1.36M | 683.00K | 10.00K |
| Gross Profit | -11.24M | -37.62M | 1.92M | 3.73M | 683.00K | 2.51M |
| EBITDA | -41.42M | -36.89M | -37.40M | -38.02M | -26.79M | -15.46M |
| Net Income | -45.31M | -44.50M | -41.05M | -41.44M | -29.09M | -15.63M |
Balance Sheet | ||||||
| Total Assets | 43.84M | 50.86M | 41.97M | 49.22M | 30.95M | 40.20M |
| Cash, Cash Equivalents and Short-Term Investments | 12.93M | 9.07M | 9.42M | 2.68M | 11.49M | 20.33M |
| Total Debt | 0.00 | 5.30M | 67.00K | 11.67M | 867.00K | 1.27M |
| Total Liabilities | 7.36M | 24.33M | 8.50M | 24.55M | 4.80M | 4.30M |
| Stockholders Equity | 36.48M | 26.53M | 33.47M | 24.67M | 26.15M | 35.91M |
Cash Flow | ||||||
| Free Cash Flow | -39.09M | -24.06M | -52.57M | -37.70M | -27.69M | -18.58M |
| Operating Cash Flow | -38.58M | -23.80M | -44.71M | -29.14M | -27.69M | -16.08M |
| Investing Cash Flow | -3.15M | -13.36M | -8.36M | -8.57M | 0.00 | -2.50M |
| Financing Cash Flow | 52.87M | 36.83M | 59.75M | 28.91M | 18.85M | 23.05M |
Prostatype Genomics AB Technical Analysis
Negative
0.75
Price Trends
0.72
Negative
1.00
Negative
0.79
Negative
Market Momentum
-0.09
Negative
36.45
Neutral
41.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Negative. The current price of 0.75 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.72, and below the 200-day MA of 0.79, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 36.45 is Neutral, neither overbought nor oversold. The STOCH value of 41.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PROGEN.
Prostatype Genomics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr13.19M | -1.23 | -84.80% | ― | ― | 35.56% | |
44 Neutral | kr105.99M | -1.50 | -72.82% | ― | 33.12% | 64.71% | |
43 Neutral | kr44.95M | -1.70 | ― | 8.47% | ― | ― | |
41 Neutral | kr24.27M | -0.22 | -181.36% | ― | 198.49% | 84.60% |
* Healthcare Sector Average
SE:PROGEN
Prostatype Genomics AB
0.45
-0.77
-63.37%
SE:STABL
Stayble Therapeutics AB
0.21
-0.25
-54.75%
SE:BIOVIC.B
Biovica International AB Class B
0.37
-0.32
-46.66%
SE:LARK
CombiGene AB
2.27
0.02
0.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.